Basic Research in Cancer Health Disparities (R21 Clinical Trial Not Allowed)
ID: 335530Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Award Range

$0 - $275K

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes
Timeline
    Description

    The National Institutes of Health (NIH) is inviting grant applications for the Basic Research in Cancer Health Disparities (R21 Clinical Trial Not Allowed), aimed at exploring the biological and genetic causes of cancer health disparities. This funding opportunity encourages innovative studies that investigate biological factors associated with cancer disparities, including mechanistic research, the development of new methodologies, and secondary data analyses, with a focus on enhancing the understanding of these disparities particularly among underrepresented racial and ethnic groups. Eligible applicants include a diverse range of organizations, such as higher education institutions, nonprofits, and tribal governments, with a funding ceiling of $275,000 over a two-year period. Interested parties should submit their applications by September 7, 2024, and can direct inquiries to the NIH OER Webmaster at OERWebmaster03@od.nih.gov for further information.

    Point(s) of Contact
    Files
    Title
    Posted
    The Department of Health and Human Services, through the National Institutes of Health (NIH), invites grant applications for basic research in cancer health disparities under the R21 exploratory/developmental mechanism. This announcement encourages pilot and feasibility studies aimed at understanding biological causes related to such disparities, focusing on innovative methodologies and data analysis. The funding aims to cultivate a diverse cohort of scientists dedicated to advancing cancer health disparities research, specifically targeting issues faced by underrepresented racial and ethnic groups. Grant applications must describe novel and exploratory projects distinct from other established research avenues. Eligible applicants include higher education institutions, nonprofits, and for-profit organizations, among others. Funding is contingent upon NIH appropriations, with a two-year budget cap of $275,000. Key dates for submission and reviews are specified, emphasizing that applications should display scientific significance, innovation, and a sound methodological approach. Overall, this initiative aims to enhance understanding of the biological mechanisms behind cancer disparities and foster impactful research within underserved populations while complying with NIH’s rigorous application standards and regulatory frameworks.
    Similar Opportunities
    NCI Clinical and Translational Exploratory/Developmental Studies (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity through the R21 Clinical Trial Optional mechanism, aimed at supporting exploratory and developmental research in cancer diagnosis, treatment, imaging, symptom management, and prevention. This grant is designed to encourage innovative studies that challenge existing paradigms and address critical barriers in cancer research, particularly focusing on reducing disparities among underserved populations. Eligible applicants include a wide range of organizations, such as historically black colleges, tribal governments, and faith-based organizations, with a maximum funding amount of $275,000 available over a two-year period. Interested parties can find more information and application details at the provided link, with a submission deadline of July 1, 2025, and inquiries directed to the NIH OER Webmaster at OERWebmaster03@od.nih.gov.
    Exploratory Grant Award to Promote Workforce Diversity in Basic Cancer Research (R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Cancer Institute (NCI), has announced the "Exploratory Grant Award to Promote Workforce Diversity in Basic Cancer Research" (R21 Clinical Trial Not Allowed). This funding opportunity aims to enhance diversity among early-stage and junior investigators in cancer research, particularly from groups that are underrepresented in the biomedical, behavioral, clinical, and social sciences. The initiative encourages innovative studies in cancer biology, with a maximum funding amount of $275,000 available over a two-year period, and applications must demonstrate scientific merit and innovation. The application window opens on May 17, 2024, with the first awards expected to be made in June 2024; interested applicants can find more information and submission guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov.
    NIMHD Exploratory/Developmental Research Grant Program (R21 - Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the NIMHD Exploratory/Developmental Research Grant Program (R21 - Clinical Trial Optional) to support innovative research aimed at addressing minority health and health disparities in the United States. This grant invites applications for short-term exploratory projects that can either pioneer new advancements or build upon previous findings, with a maximum funding amount of $275,000 available for a two-year project period, limiting annual requests to $200,000. The program emphasizes the importance of diverse representation among applicants and encourages partnerships with relevant stakeholders, focusing on NIH-designated health disparity populations through various research methodologies. Interested applicants can find more information and submission guidelines at the provided link, with the application deadline set for May 7, 2026. For inquiries, contact NIH Grants Information at grantsinfo@nih.gov.
    Administrative Supplements to Support Cancer Disparity Collaborative Research (Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced an Administrative Supplement funding opportunity aimed at enhancing cancer disparities research through the initiative PAR-22-114. This program encourages collaborations between seasoned cancer researchers and those focused on cancer disparities, with the goal of addressing adverse differences in cancer outcomes among racial/ethnic minorities and underserved populations. The funding supports the expansion of existing NCI-funded research projects to include feasibility studies on various cancer types, with a total funding amount of $2.55 million available for up to 10 awards, each with a budget limit of $150,000 in direct costs over a 12-month period. Interested applicants must submit their proposals by January 23, 2025, and can direct inquiries to the NIH OER Webmaster at OERWebmaster03@od.nih.gov.
    Exploratory Grants in Cancer Control (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering exploratory grants (R21 Clinical Trial Optional) aimed at advancing cancer control research. This funding opportunity encourages innovative approaches to understanding cancer etiology, behavior modification, and screening techniques, focusing on the early stages of impactful research that can significantly enhance population-based cancer research. Grants will provide up to $275,000 over two years, with a maximum of $200,000 available in a single year, and applications are due by October 8, 2024. Interested applicants can find more information and contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov for inquiries.
    Interventions to expand cancer screening and preventive services to ADVANCE health in populations that experience health disparities (R01, Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Interventions to expand cancer screening and preventive services to ADVANCE health in populations that experience health disparities" (R01, Clinical Trial Required). This initiative aims to solicit applications for projects that identify and address barriers to cancer screening and preventive services, particularly in underserved populations, through multi-level interventions involving patients, clinicians, healthcare settings, and community partners. The focus is on developing evidence-based strategies to improve cancer outcomes for groups such as Black Americans, Hispanics, and Native Americans, emphasizing health equity and structured research methodologies. Interested applicants can find more details and submit proposals by January 7, 2027, with the first application due date being October 5, 2023. For inquiries, contact NIH Grants Information at grantsinfo@nih.gov, and further information is available at NIH Grants.
    Specialized Programs of Research Excellence (SPOREs) in Cancer Health Disparities and Minority Health (CHD-MH) (U54 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the Specialized Programs of Research Excellence (SPOREs) in Cancer Health Disparities and Minority Health (CHD-MH), under the funding opportunity RFA-CA-24-020. This initiative aims to establish a network of multidisciplinary programs dedicated to translational cancer research, specifically targeting prevention, early detection, treatment, and diagnosis in underserved populations affected by cancer. The program requires applicants to propose at least three research projects supported by comprehensive infrastructure, including various cores such as Administrative, Shared Resources, Developmental Research Program, and Career Enhancement Program, with a maximum budget request of $1.6 million annually over five years. Interested applicants must submit their proposals by September 27, 2024, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries. The total funding available for this opportunity is approximately $80 million, expected to be distributed among around four awards.
    Dissemination and Implementation Research in Health (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Dissemination and Implementation Research in Health (R21 Clinical Trial Optional)," aimed at supporting studies that address barriers to the adoption and sustainability of evidence-based health interventions, particularly in underserved communities. The initiative encourages research that promotes equitable access to effective practices and explores methods for discontinuing ineffective or harmful interventions, emphasizing the importance of contextual factors and multidisciplinary collaboration. Eligible applicants include a wide range of organizations such as higher education institutions, nonprofits, and tribal governments, with a maximum funding amount of $275,000 and a project period of up to two years. Interested parties can find more information and submit inquiries via the NIH OER Webmaster at OERWebmaster03@od.nih.gov, with applications due by May 7, 2025.
    Community Level Interventions to Improve Minority Health and Reduce Health Disparities (R01 - Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Community Level Interventions to Improve Minority Health and Reduce Health Disparities" (R01 - Clinical Trial Optional), aimed at supporting research that develops and tests community-level interventions to enhance minority health and mitigate health disparities. Applicants are encouraged to form collaborative partnerships with community organizations and must focus on innovative, sustainable initiatives that address health disparities through community-level determinants, employing a conceptual model to connect interventions with health outcomes. The grant provides up to $1 million in direct costs per year for a project duration of up to five years, with applications due by January 7, 2027. For further information, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage at https://grants.nih.gov/grants/guide/pa-files/PAR-24-231.html.
    Co-infection and Cancer (R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Co-infection and Cancer (R21 Clinical Trial Not Allowed)" aimed at enhancing research on the mechanisms and epidemiology of co-infections in relation to cancer development. This grant seeks innovative proposals that investigate how co-infections, particularly those involving known oncogenic agents (excluding HIV), may influence carcinogenesis and contribute to cancer disparities among diverse populations. The maximum funding amount available for each application is $275,000 over a two-year period, with applications due by November 16, 2025. Eligible applicants include a wide range of institutions and organizations, and inquiries can be directed to NIH Grants Information at grantsinfo@nih.gov.